Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives

European Journal of Clinical Pharmacology

Volumn 60, Issue 7, 2004, Pages 481-487

  Baisini, Ornella ^a   Benini, Federica ^a   Petraglia, Felice ^b   Kuhnz, Wilhelm ^c   Scalia, Santo ^d   Marschall, Hanns Ulrich ^e   Brunetti, Gabriele ^f   Tauschel, Horst Dietmar ^f   Lanzini, Alberto ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF FERRARA   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Dr Falk Pharma GmbH   (Germany)

Author keywords

Ethinylestradiol; Oral contraceptives; Ursodeoxycholic acid

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHOLAGOGUES AND CHOLERETICS; CHOLESTEROL; CONTRACEPTIVES, ORAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MENSTRUAL CYCLE; TRIGLYCERIDES; URSODEOXYCHOLIC ACID;

EID: 5344258223     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0796-2     Document Type: Article

References (38)

1. Poupon RE, Lindor KD, Cauch-Dudek K et al (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113(3):884-890
2. Beuers U, Boyer JL, Paumgartner G (1998) Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28(6):1449-1453
3. Lanzini A, Northfield TC (1990) Review article: bile acid therapy. Aliment Pharmacol Ther 4(1): 1-24
4. Barbara L, Sama C, Morselli Labate AM et al (1987) A population study on the prevalence of gallstone disease: the Sirmione study. Hepatology 7(5):913-917
5. Kim WR, Lindor KD, Locke GR III et al (2000) Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119(6):1631-1636
6. Fotherby K (1990) Interactions with oral contraceptives. Am J Obstet Gynecol 163(6):2153-2159
7. Bacon JF, Shenfield GM (1980) Pregnancy attributable to interaction between tetracycline and oral contraceptives. BMJ 280(6210):293
8. Orme ML, Back DJ (1986) Interactions between oral contraceptive steroids and broad-spectrum antibiotics. Clin Exp Dermatol 11(4):327-331
9. Goldzieher JW (1989) Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol 160(5):1260-1264
10. Orme ML, Back DJ (1990) Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 163(6):2146-2152
11. Back DJ, Grimmer SF, Orme ML et al (1988) Evaluation of committee on safety of medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 25(5):527-532
12. Goldzieher JW, Brody SA (1990) Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 163(6):2114-2119
13. Back DJ, Orme ML (1990) Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18(6):472-484
14. Guengerich FP, Martin MV, Beaune PH et al (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261(11):5051-5060
15. Guengerich FP (1990) Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 163(6):2159-2163
16. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369(1):11-23
17. Denison MS, Whitlock JP Jr (1995) Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem 270(31):18175-18178
18. Maurel P (1996) In: Ioannides C (ed) Cytochrome P450, metabolic and toxicological aspects. CRC, Boca Raton pp 214-270
19. Tanaka M, Nakura H, Tateishi T et al (1999) Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury. J Hepatol 31(2):263-270
20. Chen J, Farrell GC (1996) Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J Gastroenterol Hepatol 11(9):870-877
21. Paolini M, Pozzetti L, Piazza F et al (1999) Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes. Hepatology 30(3):730-739
22. Paolini M, Pozzetti L, Piazza F et al (2000) Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression. J Investig Med 48(1):49-59
23. Schuetz EG, Strom S, Yasuda K et al (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276(42):39411-39418
24. Bachrach WH, Hofmann AF (1982) Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I. Dig Dis Sci 27(8):737-761
25. Eusufzai S, Ericsson S, Cederlund T et al (1991) Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 32(9):1044-1048
26. Taechakraichana N, Limpaphayom K, Ninlagarn T et al (2000) A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstet Gynecol 95(1):87-94
27. Kuhnz W, Back D, Power J et al (1991) Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. Horm Res 36(1-2):63-69
28. Kuhnz W, Louton T, Back DJ et al (1993) Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay. Arzneimittelforschung 43(1):16-21
29. Marschall HU, Broome U, Einarsson C et al (2001) Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J Lipid Res 42(5):735-742
30. Baumann A, Fuhrmeister A, Brudny-Kloppel M et al (1996) Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. Contraception 54(4):235-242
31. Rey JM, Walter G (1998) Hypericum perforatum (St John's wort) in depression: pest or blessing? Med J Aust 169(11-12):583-586
32. Xie W, Radominska-Pandya A, Shi Y et al (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 98(6):3375-3380
33. Staudinger JL, Goodwin B, Jones SA et al (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98(6):3369-3374
34. Marschall HU, Griffiths WJ, Gotze U et al (1994) The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. Hepatology 20(4):845-853
35. Fischer S, Neubrand M, Paumgartner G (1993) Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum and urine. Eur J Clin Invest 23(1):28-36
36. Connelly PW, Stachenko S, MacLean DR et al (1999) The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian heart health surveys research group. Can J Cardiol 15(4):419-427
37. Greenlund KJ, Webber LS, Srinivasan S et al (1997) Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa heart study. Ann Epidemiol 7(8):561-567
38. Bremmelgaard A, Sjovall J (1979) Bile acid profiles in urine of patients with liver diseases. Eur J Clin Invest 9(5):341-348